Morgan Stanley Downgrades Inspire Pharmaceuticals (ISPH) to Underweight
More News related to ISPH
- Inspire Pharma (ISPH) posts Q3 Loss of $0.12, Bests By 3c
- Inspire Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
- Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results
More News related to Downgrades
- BGB Securities Downgrades Helmerich & Payne (HP) to Sell
- Sidoti & Co Downgrades Waste Services (WSII) to Neutral
- William Blair Downgrades Strayer (STRA), ITT (ESI) to Market Perform
- D.A. Davidson Downgrades Rocky Brands (RCKY) to Underperform
- SunTrust Downgrades CKE Restaurants (CKR) to Neutral
Morgan Stanley downgrades Inspire Pharmaceuticals (Nasdaq: ISPH) from Equalweight to Underweight.
Inspire Pharmaceuticals, Inc. (Inspire) is a biopharmaceutical company focusing on discovering, developing and commercializing prescription pharmaceutical products in disease areas with commercial potential or unmet medical needs.
Related Categories
DowngradesStocks Mentioned
+0.05Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
